gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BIAFTechnologyR&D — Physical & Biological Sciences

bioAffinity Technologies, Inc. Common Stock (BIAF)

$2.65−9.56%
Close Nov 5, 2026 · split-adjusted
Nov 4, 2026$2.93▼ 90.65% in range
Nov 4, 2025Low $2.80 · High $90.00Nov 4, 2026
What changed · written from our data
As of Nov 5, 2026

bioAffinity Technologies closed at $2.65 on Nov 5, down 9.56%, within 0.0% of its 52-week closing low. Volume of 58.0K shares was 0.03× its 20-day average (below normal).

Split-adjusted performance: -57.0% over one month, -91.7% over six months, -91.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.51M, up 19.0% from a year earlier, with a net margin of -222.8%.

Short interest was 66.7K shares at the Oct 15 settlement, down 42.3% from the prior report (11.4% of float, 1.0 days to cover).

Market cap$1.6M600.7K shares
Revenue · quarter$1.5M+19.0% YoY
Diluted EPS$-9.60—
P/E · TTM—P/S 0.3×
Net margin-222.8%Gross 100.0%
Dividend yieldNone
52-week range2.65 – 90.00−97.1% from high
Volume58.0K0.03× 20-day avg
Volatility · 60d826.2%Annualised
Short % of float11.4%1.0 days to cover
Net cash$1.8MCash $2.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −12.5%1M −57.0%3M −65.4%6M −91.7%YTD −85.0%1Y −91.5%3Y −99.5%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within R&D — Physical & Biological Sciences

Percentile among 11 companies (100 = best)

6-month momentum0
Revenue growth80
Net margin40
Value (low P/E)—
Size0

Industry medians: 6-month return +47.2%, revenue growth +8.5%, net margin −122.0%, P/E 47.5×.

Short interest

Details →
Shares short66.7K−42.3% vs prior
Days to cover1.0Settled Oct 15
% of float11.4%
Short vol. 10d51.5%of daily volume

Closest peers by size in R&D — Physical & Biological Sciences

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BIAFbioAffinity Technologies$2.65−9.56%−91.7%+19.0%−222.8%—$1.6M
ISPCiSpecimen$0.7969−5.47%−84.9%−78.7%−896.9%—$2.0MCompare
ONMDOneMedNet$4.31−5.18%−56.0%+88.4%−743.8%—$25.1MCompare
IBACIB Acquisition$10.81−0.46%−0.2%———$54.1MCompare
MXCTMaxCyte$1.34−3.60%+53.8%−14.5%−122.0%—$138.3MCompare
NRCNRC Health$26.34−2.70%+40.6%+11.0%12.3%91.1$559.0MCompare
OABIOmniAb$4.86−6.18%+230.6%+78.3%−393.9%—$708.9MCompare
ABSIAbsci$9.47−9.64%+64.7%−46.4%−10443.4%—$1.63BCompare
CRLCharles River Laboratories International$318.51−2.38%+75.3%−2.7%−0.1%—$15.26BCompare

News about bioAffinity Technologies

All news →

No recent articles focused on bioAffinity Technologies.

Quick answers

What does bioAffinity Technologies do?
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung.
What is BIAF's market cap?
$1.59M, based on the Nov 5 close of $2.65.
Does bioAffinity Technologies pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BIAF is sold short?
66.7K shares, 11.4% of float, as of Oct 15, 2026.
What sector is BIAF in?
Technology, in the R&D — Physical & Biological Sciences industry.

About bioAffinity Technologies

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

HQ: San Antonio, TX57 employeesListed Sep 1, 2022bioaffinitytech.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology